Analyst Kemp Dolliver works at BROOKLINE and is covering the the Healthcare sector with 4 price targets and ratings documented since 2022 spanning on 2 stocks.
Most recent stock forecast was given on ECOR, at 13-Jan-2023.
Analyst best performing recommendations are on VRCA (VERRICA PHARMACEUTICALS INC).
Currently, out of the existing stock ratings of Kemp Dolliver - 2 which are a Buy (100%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
8
$3.13 (64.27%)
7
1 months 14 days ago
0/4 (0%)
$-3.06 (-12.89%)
Buy
1.25
$-3.62 (-74.33%)
4 months 19 days ago
0/1 (0%)
$-3.28 (-72.41%)
